Search

Displaying results 9241 - 9250 of 10000 in total
  1. Drug

    AD 337

    go.drugbank.com/drugs/DB05725
    Investigational

    AD 337 was under investigation in clinical trial NCT00377039 (A Multicentre Trial to Determine the Efficacy and Safety of AD-337 in the Treatment of Fibromyalgia).

  2. Drug

    AVI-5126

    go.drugbank.com/drugs/DB05726
    Investigational

    AVI-526 works by silencing a gene known as c-myc, a key regulatory gene involved in cardiovascular restenosis.

  3. Drug

    CYT006-AngQb

    go.drugbank.com/drugs/DB05739
    Investigational

    CYT006-AngQb is a therapeutic vaccine in development for treatment of hypertension. … It is a unique treatment modality that aims to address the issue of patient compliance by offering convenient dosing schedules due to the long-lasting effect induced by vaccination.

  4. Drug

    Drinabant

    go.drugbank.com/drugs/DB05750
    Investigational

    AVE-1625 is an oral selective and potent antagonist of cannabinoid 1 (CB1) receptors having the same mechanism of action as rimonabant. It is currently developed in obesity and its associated comorbidities. AVE-1625 is also being develop...

  5. Drug

    VSF-173

    go.drugbank.com/drugs/DB05753
    Investigational

    Study shows that VSF-173 possesses a novel mechanism to address disorders of excessive sleepiness. … It is an oral compound that has demonstrated effects on animal sleep/wake patterns and gene expression patterns suggestive of a stimulant effect.

  6. Drug

    IPH 1101

    go.drugbank.com/drugs/DB05754
    Experimental

    IPH 1101 is a chemically-synthesized structural analog of non-conventional bacterial phosphoantigens which specifically activate the Vγ9Vδ2 T cell subset.

  7. Drug

    PAC-113

    go.drugbank.com/drugs/DB05756
    Investigational

    It is a 12 amino-acid antimicrobial peptide derived from a naturally occurring histatin protein found in saliva.

  8. Drug

    DNB-001

    go.drugbank.com/drugs/DB05757
    Investigational

    DNB-001 is a first-in-class oral therapy with dual mechanism of action, which is initially being developed for the treatment of glaucoma.

  9. Drug

    Alkaline Phosphatase

    go.drugbank.com/drugs/DB05768
    Investigational

    Alkaline Phosphatase (AP) is an oral treatment and has a very favorable side-effect profile.

  10. Drug

    Arylacenamide

    go.drugbank.com/drugs/DB05792
    Experimental

    It is a dual agent with both immunomodulatory and antiproliferative activities. … Arylacenamide (SR31747) is a peripheral [sigma] ligand that binds four proteins in human cells, i.e. SRBP-1, [sigma]-2, HSI and its relative SRBP-2.